Ignite Creation Date:
2024-05-06 @ 7:43 AM
Last Modification Date:
2024-10-26 @ 11:51 AM
Study NCT ID:
NCT02580864
Status:
COMPLETED
Last Update Posted:
2019-07-23
First Post:
2015-09-16
Brief Title:
Bologna IBD Markers
Sponsor:
Société des Produits Nestlé SPN
Organization:
Société des Produits Nestlé SPN
Study Overview
Official Title:
Predictive Factors of Anti-TNFalfa-induced Deep Remission in Crohns Disease
Status:
COMPLETED
Status Verified Date:
2019-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Individuate possible predictive factors of anti-TNFalfa-induced deep remission in Crohns disease
Detailed Description:
This trial will be exploratory open in vitro study on human tissues 120 patients will be enrolled Caucasian malefemale18-65 years old with moderate-severe active Crohns disease and with indication for anti-TNF therapy according to the normal clinical practice
Simultaneously 30 no-IBD controls with no GI disorders as defined by medical history and standard clinical chemistry values afferent to the out-patient clinic will be enrolled
Simultaneously 30 no-IBD controls with no GI disorders as defined by medical history and standard clinical chemistry values afferent to the out-patient clinic will be enrolled
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None